三名WAVE董事在公司损失和低于估计的结果中出售了195万美元股票。 Three WAVE directors sold $1.95M in stock amid company loss and below-estimate results.

2025年12月8日,三名WAVE生命科学主任——Christian Henry、Gregory Verdine和Mark Corrigan——出售了129 560份股份,共计约195万美元。 On December 8, 2025, three WAVE Life Sciences directors—Christian Henry, Gregory Verdine, and Mark Corrigan—sold a combined 129,560 shares, totaling approximately $1.95 million. 这些交易在证交会档案中披露,大大减少了它们的股份,亨利的股权降低了88%。 The transactions, disclosed in SEC filings, reduced their stakes significantly, with Henry’s ownership dropping 88%. 该公司报告,每股季度损失3.2美元,收入761万美元,两者均低于估计数。 The company reported a quarterly loss of $0.32 per share and $7.61 million in revenue, both below estimates. WVE股票于12月10日以20.23美元关闭, WVE stock closed at $20.23 on December 10, down $1.08, with elevated trading volume. 该公司是一家临床阶段生物技术公司,利用其RNA疗法PRISM平台,其市场上限为33.8亿美元,并获得协商一致的“Moderate Buy”评级,目标价格为27.46美元。 The firm, a clinical-stage biotech using its PRISM platform for RNA therapies, has a market cap of $3.38 billion and a consensus “Moderate Buy” rating with a $27.46 target price.